• Special Issue Topic

    Antibody-Drug Conjugates

    Submission Deadline: October 31, 2021

    Guest Editors

    Dr. Francesco Bertoni E-Mail

    Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland

    Research Keywords: lymphoma; novel drugs; genomics; BET; PI3K


    Dr. Anastasios Stathis E-Mail

    Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland


    About the Special Issue

    Antibody drug conjugates (ADCs) have become a potent modality to treat solid tumors and hematologic malignancies. The use of antibodies against antigens that are the most specific as possible for cancer cells and that bear particular biologic features allow the delivery of powerful payloads, which otherwise would be too toxic. 

    With some of the first-generation compounds already approved by regulatory agencies, there is still wide room for further improvements of this therapeutic approach. ADC-incorporating regimens, novel linkers, novel targets, novel payloads are all exciting fields of preclinical and clinical research.

    This special issue of Exploration of Targeted Anti-tumor Therapy covers all the aspects of the use of ADCs, inviting investigators to submit their novel lab and clinical findings.

    Keywords: Antibody drug conjugate; ADC; payload; linker; antibody

    Call for Papers

    Published Articles

    Open Access
    Review
    Antibody-drug conjugates: beyond current approvals and potential future strategies
    The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits [...] Read more.
    Siddharth Menon ... Hui K. Gan
    Published: April 28, 2022 Explor Target Antitumor Ther. 2022;3:252–277
    DOI: https://doi.org/10.37349/etat.2022.00082
    View:1028
    Download:76
    Times Cited: 0
    Open Access
    Review
    Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicit [...] Read more.
    Marta Nerone ... Ilaria Colombo
    Published: April 19, 2022 Explor Target Antitumor Ther. 2022;3:149–171
    DOI: https://doi.org/10.37349/etat.2022.00077
    View:835
    Download:44
    Times Cited: 0
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist [...] Read more.
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
    DOI: https://doi.org/10.37349/etat.2022.00069
    Open Access
    Review
    Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
    Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel a [...] Read more.
    Monique Hartley-Brown, Paul Richardson
    Published: January 14, 2022 Explor Target Antitumor Ther. 2022;3:1–10
    DOI: https://doi.org/10.37349/etat.2022.00067
    View:1144
    Download:93
    Open Access
    Original Article
    Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
    Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chrom [...] Read more.
    Tomohiro Fujii ... Yutaka Matsuda
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:576–585
    DOI: https://doi.org/10.37349/etat.2021.00064